Ester C Sabino (@estercsabino) 's Twitter Profile
Ester C Sabino

@estercsabino

Full Professor Department of Pathology, Faculdade de Medicina da Universidade de São Paulo. Member of the Brazilian Academy of Science.

ID: 53805771

calendar_today05-07-2009 01:19:32

4,4K Tweet

6,6K Followers

558 Following

Nature Portfolio (@natureportfolio) 's Twitter Profile Photo

A study published in Nature Aging reports that molecular changes during aging are nonlinear with two major waves of age-related changes at approximately 44 years and 60 years of age. go.nature.com/3SPblnS

A study published in <a href="/NatureAging/">Nature Aging</a> reports that molecular changes during aging are nonlinear with two major waves of age-related changes at approximately 44 years and 60 years of age. go.nature.com/3SPblnS
Prof Sam Kariuki, BVM, MSc, PhD, DSc (Hons, LSTM) (@eadirectordndi) 's Twitter Profile Photo

The spread of Kala-azar in E. Africa is being fueled by climate change & limited access to healthcare. Strengthening disease surveillance, improving treatment access among others can go a long way. David Njagi delves more in this Devex piece. #beatNTDs bit.ly/3MgW0Zr

Scientific American (@sciam) 's Twitter Profile Photo

Understanding genetics, immunology and the microbiomes of people with inflammatory bowel disease could aid in finding the right treatments for the condition trib.al/AvAbPhJ

Critical Care Science (@critcarescience) 's Twitter Profile Photo

Introducing our Editorial Board Juliana Ferreira MD, PhD is an Assoc Prof in Cardiopneumology at Univ. of São Paulo (USP). She has a PhD in Pulmonology (USP/ Harvard Medical School) Her research interests include mechanical, global health & medical education. #CriticalCareScience #CCS

Introducing our Editorial Board
Juliana Ferreira MD, PhD is an Assoc Prof in Cardiopneumology at Univ. of São Paulo (USP). 
She has a PhD in Pulmonology (USP/ <a href="/harvardmed/">Harvard Medical School</a>)
Her research interests include mechanical, global health &amp; medical education. 

#CriticalCareScience #CCS
Prof. Akiko Iwasaki (@virusesimmunity) 's Twitter Profile Photo

Much-needed data on the genetics of #longCOVID in a new preprint by 23andMe Research - GWAS of #LongCOVID identified 3 loci pointing to immune and thrombo-inflammatory mechanisms 🔥 Ninad Chaudhary 1) HLA-DQA1–HLA-DQB 2) ABO 3) BPTF–KPAN2–C17orf58 (1/) medrxiv.org/content/10.110…

Much-needed data on the genetics of #longCOVID in a new preprint by <a href="/23andMeResearch/">23andMe Research</a>  - GWAS of #LongCOVID identified 3 loci pointing to immune and thrombo-inflammatory mechanisms 🔥 <a href="/ninaadsc/">Ninad Chaudhary</a> 
1) HLA-DQA1–HLA-DQB 
2) ABO
3) BPTF–KPAN2–C17orf58
(1/)
medrxiv.org/content/10.110…
Ester C Sabino (@estercsabino) 's Twitter Profile Photo

Re-emergence of Oropouche virus between 2023 and 2024 in Brazil: an observational epidemiological study - The Lancet Infectious Diseases thelancet.com/journals/lanin…

Hospital das Clínicas de São Paulo (@hospitalhcfmusp) 's Twitter Profile Photo

O HCFMUSP desenvolve novo modelo de teleinterconsulta com integração de equipamentos de beira leito: a TeleUTI Conectada, projeto desenvolvido em parceria com o Ministério da Saúde. Saiba mais: x.gd/wemvK.

O HCFMUSP desenvolve novo modelo de teleinterconsulta com integração de equipamentos de beira leito: a TeleUTI Conectada, projeto desenvolvido em parceria com o Ministério da Saúde. Saiba mais: x.gd/wemvK.
Instituto Todos pela Saúde (ITpS) (@todospelasaude) 's Twitter Profile Photo

Um estudo com doadores de sangue em São Paulo revelou que 72% nunca tiveram contato com nenhum dos quatro sorotipos da dengue. Isso significa que a maior parte dessa população não possui anticorpos contra a doença. (1/4)

Um estudo com doadores de sangue em São Paulo revelou que 72% nunca tiveram contato com nenhum dos quatro sorotipos da dengue. Isso significa que a maior parte dessa população não possui anticorpos contra a doença.

(1/4)
Ester C Sabino (@estercsabino) 's Twitter Profile Photo

Bimodal distributions of anti-Trypanosoma cruzi antibody levels in blood donors are associated with parasite detection and antibody waning in peripheral blood. medrxiv.org/content/10.110…

TWAS - The World Academy of Sciences (@twasnews) 's Twitter Profile Photo

Co-winner of the same award, Ester C Sabino of USP - Universidade de São Paulo in Brazil, said: "...awards like this, which focus on developing countries, are invaluable—they contribute to making science more visible and accessible in these countries."

Co-winner of the same award, <a href="/estercsabino/">Ester C Sabino</a> of <a href="/usponline/">USP - Universidade de São Paulo</a> in Brazil, said: "...awards like this, which focus on developing countries, are invaluable—they contribute to making science more visible and accessible in these countries."
EID journal (@eidjournal) 's Twitter Profile Photo

A systematic review examining 30 reported cases of #AvianInfluenza in pregnant women found high mortality rates for mothers (90.0%, 27/30) and their babies (86.7%, 26/30) when women were infected with avian influenza virus during pregnancy. bit.ly/41CoMg9

A systematic review examining 30 reported cases of #AvianInfluenza in pregnant women found high mortality rates for mothers (90.0%, 27/30) and their babies (86.7%, 26/30) when women were infected with avian influenza virus during pregnancy.
bit.ly/41CoMg9
Tabata Amaral (@tabataamaralsp) 's Twitter Profile Photo

Jair Bolsonaro de volta ao poder sem eleição e sem data pra sair: essa podia ser a realidade do Brasil hoje. A nossa sorte é que o líder desse plano era um político com uma trajetória consistente de fracasso e incompetência. Que Jair Bolsonaro tenha o amplo direito de defesa que

Instituto Todos pela Saúde (ITpS) (@todospelasaude) 's Twitter Profile Photo

VACINA CONTRA CHIKUNGUNYA APROVADA PELA ANVISA 🚨Imunizante pode ser aplicado na população com mais de 18 anos, mas ainda não será disponibilizado pelo SUS. Para que isso aconteça, novos processos regulatórios devem ser cumpridos. (1/2)

VACINA CONTRA CHIKUNGUNYA APROVADA PELA ANVISA 🚨Imunizante pode ser aplicado na população com mais de 18 anos, mas ainda não será disponibilizado pelo SUS. Para que isso aconteça, novos processos regulatórios devem ser cumpridos.  

(1/2)